NCT07353645 2026-04-15
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2 Recruiting
Clinical Trials
25 trialsNCT06468280 2026-01-21
ROSETTE
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT04146298 2025-12-24
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Changhai Hospital
Phase 1/2 Recruiting
NCT06008054 2025-09-26
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT05941507 2025-09-24
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2 Recruiting
NCT05576480 2025-08-28
SPARC
Ruijin Hospital
Phase 2 Recruiting
NCT06507371 2025-06-26
mRCAT-III
Sir Run Run Shaw Hospital
Phase 3 Recruiting
NCT06280495 2025-05-30
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
Phase 2/3 Recruiting
NCT06908031 2025-05-14
CRIT
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Recruiting
NCT06794086 2025-05-13
SPARKLE-L
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Recruiting
NCT06928584 2025-04-15
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
Fudan University
Phase 2 Recruiting
NCT05713994 2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
NCT06840665 2025-02-21
MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer
Fudan University
Phase 2 Recruiting
NCT06792162 2025-01-24
PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
Peking University Third Hospital
Phase 2 Recruiting
NCT05555888 2025-01-15
TORCH-E
Fudan University
Phase 2 Recruiting
NCT06417892 2025-01-14
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recruiting
NCT05972655 2025-01-09
mRCAT
Sir Run Run Shaw Hospital
Phase 2 Recruiting
NCT05628038 2024-10-01
TORCH-R
Fudan University
Phase 2 Recruiting
NCT06349044 2024-08-27
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
Zhejiang Cancer Hospital
Phase NA Recruiting
NCT05717738 2024-06-13
CCGLC-008
Tongji Hospital
Recruiting
NCT06455124 2024-06-13
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)
Fudan University
Phase 2 Recruiting
NCT06396637 2024-05-02
PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC
Sun Yat-sen University
Phase 2 Recruiting
NCT06121700 2023-11-08
Miracle-G
Fudan University
Phase 2 Recruiting
NCT06122493 2023-11-08
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Ruijin Hospital
Phase 2 Recruiting
NCT04973306 2022-06-30
iCROSS
Shanghai Zhongshan Hospital
Phase 2/3 Recruiting